# Sisaf

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sisaf

- Industry: Biotechnology
- Headquarters: Guildford, UK
- Website: www.sisaf.com
- Total disclosed funding: $22M
- Latest round: Series B (Jul 9, 2019)
- Investors on record: 5

## About

Sisaf Limited is a biopharmaceutical company focused on pioneering RNA delivery solutions and therapeutics through their innovative Bio-Courier® technology, which enhances the effectiveness of nucleic acids in treating various medical conditions.Founded in 2006 and headquartered in Guildford, UK, Sisaf Limited specializes in RNA therapeutics and has completed a total of 4 deals. The company raised GBP 5.51 million in a SERIES B funding round on July 9, 2019, led by Vickers Venture Partners and supported by Future Fund. The founder's history is not publicly detailed, and no subsidiaries or parent companies are mentioned. The latest funding round represents the total amount raised by the firm to date, bringing the total to GBP 5.51 million, with a current valuation of GBP 171.904 million.SiSaf Ltd specializes in innovative RNA delivery and therapeutics, primarily utilizing its proprietary Bio-Courier® technology, which integrates bioabsorbable silicon with organic materials. This technology enhances the delivery of nucleic acids across a range of therapeutic applications, effectively addressing shortcomings associated with conventional delivery methods such as lipid nanoparticles. SiSaf's primary focus areas include the development of RNA therapeutics for solid tumors, such as pancreatic ductal adenocarcinoma, metastatic cancers, and rare skeletal disorders like autosomal dominant Osteopetrosis Type II. The company targets healthcare providers, research institutions, and pharmaceutical partners, with its products expected to be utilized in clinical settings primarily within Europe and North America, reflecting its commitment to tackling significant medical challenges through advanced biopharmaceutical solutions.SiSaf Ltd generates revenue through strategic partnerships and licensing agreements, particularly in the biopharmaceutical sector. The company engages in business-to-business transactions, collaborating with research institutions and pharmaceutical companies to develop and commercialize RNA-based therapies. Typical agreements may involve upfront payments, milestone payments linked to specific development targets, and royalties based on product sales once commercialized. The flagship Bio-Courier® technology serves as a cornerstone of its offerings, enhancing the therapeutic delivery of RNA molecules and aiming to penetrate various markets, including oncology and rare genetic disorders. While specific pricing details for its services and products are not publicly disclosed, the revenue model emphasizes long-term collaborations that facilitate the development of cutting-edge RNA therapeutics.Sisaf Limited plans to leverage the recent funding of GBP 5.51 million raised in July 2019 to further develop its innovative RNA delivery technologies. The company aims to expand its product offerings and is currently designing new RNA therapeutics targeting solid tumors and rare genetic disorders, with potential launches expected in the next few years. Additionally, Sisaf is exploring opportunities to penetrate new geographic markets, specifically targeting regions in Asia and the Americas by 2025, to broaden its reach and impact in the biopharmaceutical industry.

## Funding rounds

- Series B, Jul 9, 2019, $6.9M — Vickers Venture Partners, Future Fund
- Series A, Mar 26, 2018, $7.9M — Innovation Ulster, Vickers Venture Partners, Invest Northern Ireland
- Series A, Jun 28, 2016, $7M — Vickers Venture Partners, Invest Northern Ireland, Exen Capital

## Investors

- Vickers Venture Partners (https://capitalatlas.ai/funds/vickers-venture-partners) — Series A, Series B
- Invest Northern Ireland — Series A
- Exen Capital — Series A
- Innovation Ulster (https://capitalatlas.ai/funds/innovation-ulster) — Series A
- Future Fund — Series B